Proactive Investors - Run By Investors For Investors

PreveCeutical Medical stock soars, but company says not aware of reasons behind rally

Shares of the health sciences company soar sharply in both Canada and New York
Medical charts
PreveCeutical is a health sciences company.

PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) shares closed sharply higher on Tuesday, but the company said it was not aware of any reason behind the stock's surge.

"At the request of the Investment Industry Regulatory Organization of Canada (IIROC), (the company) confirms that its management is not aware of any undisclosed corporate development or material change to the company or its operations that would account for the recent increase in market activity," a statement said.

Shares of PreveCeutical in Canada closed 50% higher at C$0.06, while its stock in New York settled 53.33% stronger at US$0.46. 

BIG PICTURE: PreveCeutical Medical reaches major milestone in its Australia Sol-Gel research program

PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

The company currently has five research and development programs.

They include a dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

The company is based in Vancouver, British Columbia.

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use